Get started
Entera Bio Ltd.Entera Bio Ltd.Entera Bio Ltd.

Entera Bio Ltd.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptions

Market insights

ENTX Stock Analysis 1W 24/06/21Hello everyone , as we all know the market action discounts everything :) We can tell from all the signs and indicators that the ENTX stock is moving in a strong uptrend , all the data that we gathered and saw on the chart looks makes the market is in a great place to buy . I am seeing 2 ways the market is possibly moving in the next few weeks : 1_The market is gonna continue to go up and could reach new highs such as 8.6 2_The market is gonna be moving in the boundaries of the ascending triangle then breaking the resistance line at 7 and keeps going up Until we have a bearish reversal ***** Fundamental analysis : Entera Bio Ltd.'s (ENTX) share price surged 44.8% to close at $6.50 on June 23. Entera Bio is a developer of orally delivered large molecule and biologic therapeutics. The company continues to witness developments and improvements in drug research in 2021, winning the confidence of its investors and seeing its share price rise to a new high. With a market capital of 154.5 million, the share price of Entera Bio has almost tripled recently. It has skyrocketed 507.5% and 233.3% over the past six months and a year, respectively. On June 23, the company announced its Phase 2 progress related to the treatment of osteoporosis, a bone disease. Entera Bio CEO Spiros Jamas said “We are looking forward to an end of Phase 2 meeting with the FDA. More detailed results will also be presented in a future scientific conference and publications. The company will evaluate potential additional osteoporosis market opportunities specifically related to increases in hip BMD.” Per a study from Reportlinker.com, the global osteoporosis drugs market is projected to grow to $20.17 billion by 2026. This represents a CAGR of 6.83% from 2020 through 2026. Make sure to Follow and Like for more content If you have any questions please ask Thank you for reading.
NASDAQ:ENTXLong
by GabiDahduh
9
ENTX - Entera Bio Ltd on huge run - possible double againI bought this one several days ago and there is still a huge amount of upside. If it can get through the $4.30 and $4.80 resistance a double is a real deal. They have had solid revenues the last 2 Q and are based in Isreal. They have partnered in a project with Amgen and have been around I think since 2003. The Timeframes tell the story and the flow of the chart and long build up shows possible huge rewards near term. I am long for this company, but relatively short for this run...I think by next week we will be above $5 or $5.50.
NASDAQ:ENTXShort
by sid72
2
ENTX : Downside Vs Upside AnalysisTrend breakout analysis for ENTX: Much more upside than downside from here as consolidation persists. News from final 6months interim coming up in Q2 could bring good Volume back to this stock. Shorts have been taking this stock hostage for a while now.. Longs will have a nice come back to newer highs if results are significant enough. If you have any comments, opinions or something constructive to add.. Please feel free to do so! Best regards, Moder8
NASDAQ:ENTXLong
by Moder8
$ENTX PT 6-10 and higherEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
NASDAQ:ENTXLong
by UnknownUnicorn19246015
1
ENTX: Bullish Flag (107%)Bullish Flag (107%) Pros: Volume during post formation Descending volume during flag formation Golden cross in blue PPS above 50MA and 200MA RS above 0 and ascending R/R ratio above 5 ATR ascending 200MA ascending, barely 250RSI above 50 and ascending Cons: Gap may be filled back to 1.60$ Target: PT = 10.87$ Help how ever you can to keep this alive. Thank you to those who have donated Coins! Always do your own due dilligence. This is not financial advice Stay Humble, have fun, make money! Education: www.dailyfx.com
NASDAQ:ENTXLong
by LeLaf
4
$ENTX Entera Bio Ltd Announces Positive Topline EB613 Phase 2Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data ‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21 ‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo. ‒ Similar to the increase in P1NP, a significant increase in Osteocalcin was also observed in the 2.5 mg group after 3 months (P <0.01). ‒ In line with a potential anabolic effect, a significant decrease in CTX was observed after 3 months of treatment (P <0.015). The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMDand a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment. ‒ Entera intends to submit the full dataset for publication and/or presentation at an upcoming medical conference.
NASDAQ:ENTX
by AlenCiken